278 related articles for article (PubMed ID: 28059098)
21. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P
Oncology; 2019; 96(3):147-155. PubMed ID: 30282082
[TBL] [Abstract][Full Text] [Related]
22. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.
Hu Y; Ye Z; Wang F; Qin Y; Xu X; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():679000. PubMed ID: 34093445
[TBL] [Abstract][Full Text] [Related]
23. Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin.
Mai R; Kaemmerer D; Träger T; Neubauer E; Sänger J; Baum RP; Schulz S; Lupp A
Sci Rep; 2019 Mar; 9(1):4339. PubMed ID: 30867449
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
[TBL] [Abstract][Full Text] [Related]
25. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls.
Konukiewitz B; Jesinghaus M; Kasajima A; Klöppel G
Virchows Arch; 2022 Feb; 480(2):247-257. PubMed ID: 34647171
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.
Chen SF; Kasajima A; Yazdani S; Chan MS; Wang L; He YY; Gao HW; Sasano H
Hum Pathol; 2013 Oct; 44(10):2199-203. PubMed ID: 23954140
[TBL] [Abstract][Full Text] [Related]
28. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.
Guenter R; Aweda T; Carmona Matos DM; Jang S; Whitt J; Cheng YQ; Liu XM; Chen H; Lapi SE; Jaskula-Sztul R
Surgery; 2020 Jan; 167(1):189-196. PubMed ID: 31629542
[TBL] [Abstract][Full Text] [Related]
31. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.
Rindi G; Mete O; Uccella S; Basturk O; La Rosa S; Brosens LAA; Ezzat S; de Herder WW; Klimstra DS; Papotti M; Asa SL
Endocr Pathol; 2022 Mar; 33(1):115-154. PubMed ID: 35294740
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic neuroendocrine tumors with somatostatin expression and paraganglioma-like features.
Konukiewitz B; von Hornstein M; Jesinghaus M; Steiger K; Weichert W; Detlefsen S; Kasajima A; Klöppel G
Hum Pathol; 2020 Aug; 102():79-87. PubMed ID: 32668277
[TBL] [Abstract][Full Text] [Related]
33. Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss.
Fan Y; Fan H; Quan Z; Wu X
Cancer Invest; 2021 May; 39(5):423-434. PubMed ID: 33683975
[TBL] [Abstract][Full Text] [Related]
34. Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors.
Matsukuma K; Olson KA; Gui D; Gandour-Edwards R; Li Y; Beckett L
Mod Pathol; 2017 Apr; 30(4):620-629. PubMed ID: 28084345
[TBL] [Abstract][Full Text] [Related]
35. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes.
Okuwaki K; Kida M; Mikami T; Yamauchi H; Imaizumi H; Miyazawa S; Iwai T; Takezawa M; Saegusa M; Watanabe M; Koizumi W
Cancer; 2013 Dec; 119(23):4094-102. PubMed ID: 24022344
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study.
Diakatou E; Kaltsas G; Tzivras M; Kanakis G; Papaliodi E; Kontogeorgos G
Endocr Pathol; 2011 Mar; 22(1):24-30. PubMed ID: 21287294
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
[TBL] [Abstract][Full Text] [Related]
39. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
40. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
